Know Cancer

or
forgot password

TRANSORCE (A Sub-Study of SORCE)


N/A
18 Years
N/A
Open (Enrolling)
Both
Kidney Cancer

Thank you

Trial Information

TRANSORCE (A Sub-Study of SORCE)


OBJECTIVES:

- Examine the relationship between tumor genotype, expression, and patient outcome.

- Examine the relationship between constitutional genotype and patient outcome.

OUTLINE: This is a multicenter study.

Patients undergo blood and/or tissue sample collection for laboratory studies. Laboratory
studies include generation of tissue microarrays; analysis of protein expression by
immunohistochemistry; tumor DNA extraction and whole genome amplification; detection of VHL
or other relevant gene mutations by direct sequencing; and constitutional (lymphocyte DNA)
genotyping by single nucleotide polymorphism analysis.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed resected renal cell carcinoma

- Clear cell or non-clear cell tumor

- Receiving sorafenib tosylate on clinical trial MRC-RE05-SORCE

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Relationship between tumor genotype, expression, and patient outcome

Safety Issue:

No

Principal Investigator

Timothy Eisen

Investigator Role:

Study Chair

Investigator Affiliation:

Cancer Research UK at Cambridge Research Institute

Authority:

Unspecified

Study ID:

CDR0000601175

NCT ID:

NCT00900536

Start Date:

July 2007

Completion Date:

Related Keywords:

  • Kidney Cancer
  • clear cell renal cell carcinoma
  • stage I renal cell cancer
  • stage II renal cell cancer
  • stage III renal cell cancer
  • stage IV renal cell cancer
  • papillary renal cell carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Name

Location